Congress Materials

Medical Information
Saudi Arabia
 

This medical Information website is intended only for Healthcare Professionals in the Kingdom of Saudi Arabia. This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient.

Please choose the category that best describes you.

This content is intended for Healthcare professionals in Saudi Arabia. Would you like to proceed?

I am a healthcare professional registered to practice in KSAYes, I am a healthcare professional registered to practice in KSA
SelectI am a healthcare professional registered to practice in KSAYes, I am a healthcare professional registered to practice in KSA
I am not a healthcare professionalNo, go back to the patient portal
SelectI am not a healthcare professionalNo, go back to the patient portal
Non-Saudi Arabia residents click here.
The information on this page pertains to select congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.
Poster
Lewis MA, Stansfield L, Kelton JM, Edwards M, Lieu CH. January 20, 2022 ASCO-GI 2022 Colorectal Cancer

Biomarker Testing in Patients With Metastatic Colorectal Cancer: Perspectives From US Oncologists in Rural Areas and Urban Clusters

View Presentation
Poster
Kopetz S, Yoshino T, Kim TW, Desai J, Yaeger R, Van Cutsem E, Ciardiello F, Wasan H, Maughan T, Zhang Y, Usari T, Chung C-H, Zhang X, Tabernero J. January 20, 2022 ASCO-GI 2022 Colorectal Cancer

BREAKWATER Safety Lead-In: Encorafenib + Cetuximab ± Chemotherapy for First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer

View Presentation
Poster
Kopetz S, Murphy DA, Pu J, Yaeger R, Ciardiello F, Desai J, Van Cutsem E, Singh Wasan H, Yoshino T, Elez E, Alkuzweny B, Zhu Z, Zhang X, Tabernero J. January 20, 2022 ASCO-GI 2022 Colorectal Cancer

Evaluation of Baseline BRAF V600E Mutation in Circulating Tumor DNA and Efficacy Response From the BEACON CRC Study

View Presentation
Poster
Kopetz S, Bekaii-Saab T, Yoshino T, Chung C-H, Zhang X, Tabernero J June 4, 2022 ASCO 2022 Colorectal Cancer

SEAMARK: Randomized Phase 2 Study of Pembrolizumab + Encorafenib + Cetuximab vs Pembrolizumab Alone for First-Line Treatment of BRAF V600E-Mutant Microsatellite Instability-High (MSI-H)/Mismatch Repair-Deficient (dMMR) Metastatic Colorectal Cancer (mCRC)

View Presentation View Abstract Plain Language Summary